Encorafenib and Impurities
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
Encorafenib R-Isomer REF: 4Z-E-183003CAS: 1269440-29-0 | - - - | To inquire | Fri 21 Jun 24 | |
Encorafenib-d7 REF: 4Z-E-183002CAS: 2413673-15-9 | - - - | To inquire | Fri 21 Jun 24 | |
Encorafenib REF: TM-T6487CAS: 1269440-17-6 | 99.74% | 51.00 €~350.00 € | Fri 21 Jun 24 | |
Encorafenib REF: 4Z-E-183001CAS: 1269440-17-6 | - - - | To inquire | Fri 21 Jun 24 |
Ref: 4Z-E-183003
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Friday 21 Jun 2024
Ref: 4Z-E-183002
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Friday 21 Jun 2024
Encorafenib
CAS:1269440-17-6
Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
Formula:
C22H27ClFN7O4S
Purity:
99.74%
Color and Shape:
Solid
Molecular weight:
540.01
Ref: TM-T6487
1mg | 51.00 € | ||
5mg | 93.00 € | ||
10mg | 120.00 € | ||
25mg | 184.00 € | ||
50mg | 350.00 € |
Estimated delivery in United States, on Friday 21 Jun 2024
Ref: 4Z-E-183001
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Friday 21 Jun 2024